Table 2.

Clinical and demographic characteristics of UC patients from cohort 2. Patients’ demographics and clinical characteristics at screening [Week 0] and at Week 14. Continuous variables are described as median and IQR, and categorical variables as absolute frequencies and percentages; p-values from paired analysis between Weeks 0 and 14 are shown.

COHORT 2: Clinical and demographic characteristics
Number of cases	16
Gender [male/female]
Male	9 [56.3%]
Female	7 [43.7%]
Age [years]	41 [35–53]
Duration of disease [years]	6 [3–18]
Extent of disease
Proctitis	0 [0%]
Left-sided colitis	5 [31.3%]
Extensive colitis	11 [68.7%]
	Week 0	Week 14	p-Value
Medication			< 0.01
No treatment	2 [12.5%]	0 [0%]
5-ASA	1 [6.3%]	0 [0%]
Immunosuppressors	10 [62.5%]	0 [0%]
Anti-TNF	2 [12.5%]a	6 [37.5%]
Steroids	1 [6.3%]	0 [0%]
Combined therapy	0 [0%]	10 [62.5%]
CRP [mg/dL]	2 [0.4–3.7]	0.5 [0.04–1.9]	0.04
ESR [mm/h]	43 [17.5–66.5]	32 [15.5–44]	0.12
Platelet count [10^9/L]	368 [252–503]	265 [208–504]	0.50
Global Mayo Score	9 [8–9]	6 [2–9]	< 0.01
Endoscopic Mayo Score			0.01
Score 0	0 [0%]	1 [6.3%]
Score 1	0 [0%]	3 [18.7%]
Score 2	3 [18.7%]	3 [18.7%]
Score 3	13 [81.3%]	9 [56.3%]
MS	9 [5.8–12]	7 [2–9.8]	0.04
Neutrophils [%]	69.2 [59.6–79.1]	63.6 [56.7–73.42]	0.29
Neutrophil count [10^9/L]	5.8 [3.7–7.5]	3.2 [2.5–6.2]	0.09
N/L ratio	3.7 [2.6–6.2]	2.8 [2.1–4.4]	0.02

UC, ulcerative colitis; IQR, interquartile range; 5-ASA, 5-aminosalicylic acid; TNF, tumour necrosis factor;CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; N/L ratio; neutrophil-lymphocyte ratio; MS; Modified Score [sum of endoscopic Mayo score of each segment].

^aThese two cases were treated with an anti-TNFα drug, but stopped due to no response and started a different one.